Last Price
9.48
Today's Change
+4.59 (93.86%)
Day's Change
6.16 - 12.40
Trading Volume
94,666,959
Exchange: NASDAQ Global Select NASDAQ Global Select
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. Markus Warmuth M.D. Dr. Markus Warmuth M.D.
Full Time Employees: 129 129
IPO Date: 2021-06-24 2021-06-24
CIK: 0001826457 0001826457
ISIN: US61225M1027 US61225M1027
CUSIP: 61225M102 61225M102
Beta: 1.42 1.42
Last Dividend: 0.00 0.00
Dcf Diff: 9.40 9.40
Dcf: 1.60 1.60
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.